Table 4.
Univariate analysis for patients characteristics, treatments and mutations in patients lacking both FLT3-ITD and NPM1 alterations (n = 90 and n = 75 achieving CR).
| Patients Characteristics | CR n = 90 | OS n = 90 | DFS n = 75 | |||
|---|---|---|---|---|---|---|
| HR | p | HR | p | HR | p | |
| HDS | 0.51 (0.15–1.59) | 0.2622 | 1.29 (0.72–2.32) | 0.3877 | 1.05 (0.56–1.98) | 0.8837 |
| HSCT | - | - | 0.43 (0.21–0.89) | 0.0229 | 0.42 (0.2–0.88) | 0.0225 |
| Age > 60 | 0.51 (0.16–1.69) | 0.2524 | 2.28 (1.26–4.15) | 0.0068 | 2.63 (1.35–5.11) | 0.0043 |
| Sex male | 2.38 (0.78–7.77) | 0.1336 | 0.63 (0.35–1.13) | 0.1194 | 0.86 (0.45–1.64) | 0.6537 |
| De novo | 2.38 (0.65–7.98) | 0.1657 | 0.63 (0.33–1.22) | 0.1729 | 0.58 (0.27–1.23) | 0.1569 |
| ECOG PS 2–3 | 1 (0.15–19.93) | 1.0000 | 2.66 (0.95–7.47) | 0.0635 | 2 (0.61–6.53) | 0.2504 |
| WBC count > 50 | 1.22 (0.19–23.93) | 0.8605 | 0.54 (0.13–2.24) | 0.3955 | 0.28 (0.04–2.03) | 0.2066 |
| DNMT3A | 0.48 (0.12–2.41) | 0.3219 | 2.77 (1.32–5.8) | 0.0068 | 3.83 (1.67–8.76) | 0.0015 |
| TET2 | 0.21 (0.05–0.81) | 0.0195 | 2.26 (1.09–4.71) | 0.0286 | 2.33 (0.9–5.99) | 0.0797 |
| RUNX1 | 0.41 (0.13–1.37) | 0.1323 | 2.36 (1.28–4.35) | 0.0060 | 1.96 (0.97–3.96) | 0.0608 |
| IDH2 | 0.52 (0.15–2.13) | 0.3297 | 1.03 (0.46–2.3) | 0.9439 | 1.56 (0.68–3.54) | 0.2909 |
| CEBPA2 * | 4.5 (0.81–84.34) | 0.1598 | 0.16 (0.05–0.53) | 0.0026 | 0.12 (0.03–0.5) | 0.0035 |
| ASXL1 | 0.27 (0.08–1.03) | 0.0466 | 1.26 (0.59–2.7) | 0.5564 | 1.12 (0.44–2.86) | 0.8194 |
| CEBPA1 * | >99.99 (0–NA) | 0.9934 | 0.45 (0.14–1.45) | 0.1801 | 0.72 (0.25–2.03) | 0.5315 |
| SRSF2 | 0.08 (0.02–0.31) | 0.0003 | 1.33 (0.59–2.98) | 0.4889 | 0.7 (0.17–2.93) | 0.6305 |
| NRAS | 0.57 (0.11–4.14) | 0.5123 | 2.88 (1.28–6.48) | 0.0105 | 2.9 (1.13–7.48) | 0.0272 |
| KMT2A-PTD | 3.5 (0.62–65.89) | 0.2437 | 1.05 (0.49–2.26) | 0.8960 | 1.22 (0.56–2.66) | 0.6168 |
| STAG2 | 0.79 (0.17–5.67) | 0.7783 | 1.16 (0.45–2.98) | 0.7603 | 1.57 (0.6–4.09) | 0.3593 |
| BCOR | >99.99 (0–NA) | 0.9908 | 1.31 (0.46–3.71) | 0.6128 | 1.36 (0.48–3.9) | 0.5639 |
| KRAS | >99.99 (0–NA) | 0.9914 | 0.61 (0.08–4.44) | 0.6276 | 0.6 (0.08–4.37) | 0.6138 |
| WT1 | >99.99 (0–NA) | 0.9903 | 0.58 (0.18–1.86) | 0.3584 | 0.6 (0.18–1.96) | 0.3983 |
| GATA2 | >99.99 (0–NA) | 0.9937 | 0 (0–Inf) | 0.9973 | 0 (0–99.99) | 0.9973 |
| SF3B1 | 1.44 (0.23–28.05) | 0.7417 | 1.4 (0.59–3.3) | 0.4479 | 1.77 (0.74–4.26) | 0.2010 |
| U2AF1 | 1.67 (0.27–32.28) | 0.6406 | 3.03 (1.4–6.58) | 0.0049 | 3.89 (1.69–8.93) | 0.0014 |
* CEBPA2 and CEBPA1 indicate the presence of double or single mutation, respectively.